Login

Switch On Your HIV Smarts.

Early Antiretroviral Therapy: Progress in HIV Cure Research

Early Antiretroviral Therapy: Progress in HIV Cure Research

May 6, 2015, by

Early delivery of antiretroviral therapy (ART) soon after HIV infection holds promise as a way to reduce the size of the viral reservoir. What does this mean for HIV cure research? Read More

Injectable PrEP: The Next Order of the Day

Injectable PrEP: The Next Order of the Day

May 4, 2015, by

Two studies are currently investigating a possible long-acting injected version of PrEP. Find out more about this research and what it could mean for HIV prevention. Read More

Predicting HIV Rebound: Progress in HIV Cure Research

Predicting HIV Rebound: Progress in HIV Cure Research

April 30, 2015, by

When HIV treatment is stopped, viral load rebounds. New research that can predict viral load rebound might prove useful for researchers working on an HIV cure. Read More

Capping Coinsurance Payments for PrEP and HIV Meds

Capping Coinsurance Payments for PrEP and HIV Meds

April 29, 2015, by

Covered California will soon vote on capping the amount consumers have to pay for drugs in the “specialty” tier. Two experts explain what this will mean for people paying for HIV medications and Truvada for PrEP. Read More

DHHS: Atripla No Longer Recommended as First-Line HIV Therapy

DHHS: Atripla No Longer Recommended as First-Line HIV Therapy

April 28, 2015, by

The U.S. Department of Health and Human Services recently demoted the widely-used HIV combination pill Atripla from first-line HIV therapy recommendations, not because of a problem with the drug itself, but because of the changing landscape in HIV treatment. Read More